Short Term Intensified Pembrolizumab (Keytruda) And Tivozanib For High-Risk Renal Cell Carcinoma (STRIKE)

Sponsor:

Alliance for Clinical Trials in Oncology

Sponsor Study ID:

A032201

CTO #:

104222

NCT Number:

NCT06661720

Phase:

III

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Kidney

Study Objectives:

2.0 OBJECTIVES 2.1 Primary Objective To compare disease free survival (DFS) as assessed by the investigator for high-risk renal cell carcinoma patients treated with adjuvant pembrolizumab and tivozanib versus those receiving pembrolizumab alone. 2.2 Secondary Objectives 2.2.1 To compare overall survival (OS) for patients treated with adjuvant pembrolizumab and tivozanib versus those receiving pembrolizumab alone. 2.2.2 To assess adverse events in each study arm by CTCAE 5.0.

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)